Matching-Adjusted Indirect Comparison of the Efficacy and Safety of Difamilast 1% and Delgocitinib 0.5% in Patients with Moderate-to-Severe Atopic Dermatitis
Abstract Background Atopic dermatitis (AD) is a chronic condition with an increasing incidence in Japan. Difamilast and delgocitinib are both new topical drugs for AD proven to be efficacious and safe in phases 2 and 3 clinical trials in Japan. However, there are no head-to-head trials comparing the...
Guardat en:
| Autors principals: | , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Adis, Springer Healthcare
2024-10-01
|
| Col·lecció: | Dermatology and Therapy |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1007/s13555-024-01282-1 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|